High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

Roelof Willemze; Stefan Suciu; Giovanna Meloni; Boris Labar; Jean-Pierre Marie; Constantijn J. M. Halkes; Petra Muus; Martin Mistrik; Sergio Amadori; Giorgina Specchia; Francesco Fabbiano; Francesco Nobile; Marco Sborgia; Andrea Camera; Dominik L. D. Selleslag; Francois Lefrer̀E Sr.; Domenico Magro; Simona Sica; Nicola Cantore; Meral Beksac; Zwi Berneman; Xavier Thomas; Lorella Melillo; Jose E. Guimaraes; Pietro Leoni; Mario Luppi; Maria E. Mitra; Dominique Bron; Georges Fillet; Erik W. A. Marijt; Adriano Venditti; Anne Hagemeijer; Marco Mancini; Joop Jansen; Daniela Cilloni; Liv Meert; Paola Fazi; Marco Vignetti; Silvia M. Trisolini; Franco Mandelli; Theo De Witte

doi:10.1200/JCO.2013.51.8571

High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

Roelof Willemze, Stefan Suciu, Giovanna Meloni, Boris Labar, Jean-Pierre Marie, Constantijn J. M. Halkes, Petra Muus, Martin Mistrik, Sergio Amadori, Giorgina Specchia, Francesco Fabbiano, Francesco Nobile, Marco Sborgia, Andrea Camera, Dominik L. D. Selleslag, Francois Lefrer̀E Sr., Domenico Magro, Simona Sica, Nicola Cantore, Meral BeksacZwi Berneman, Xavier Thomas, Lorella Melillo, Jose E. Guimaraes, Pietro Leoni, Mario Luppi, Maria E. Mitra, Dominique Bron, Georges Fillet, Erik W. A. Marijt, Adriano Venditti, Anne Hagemeijer, Marco Mancini, Joop Jansen, Daniela Cilloni, Liv Meert, Paola Fazi, Marco Vignetti, Silvia M. Trisolini, Franco Mandelli, Theo De Witte

Risultato della ricerca: Contributo in rivista › Articolo in rivista

107 Citazioni (Scopus)

Abstract

Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.

Lingua originale	English
pagine (da-a)	219-228
Numero di pagine	10
Rivista	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume	32
DOI	https://doi.org/10.1200/JCO.2013.51.8571
Stato di pubblicazione	Pubblicato - 2014

Keywords

leukemia

Accesso al documento

10.1200/JCO.2013.51.8571

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Willemze, R., Suciu, S., Meloni, G., Labar, B., Marie, J.-P., Halkes, C. J. M., Muus, P., Mistrik, M., Amadori, S., Specchia, G., Fabbiano, F., Nobile, F., Sborgia, M., Camera, A., Selleslag, D. L. D., Lefrer̀E Sr., F., Magro, D., Sica, S., Cantore, N., ... De Witte, T. (2014). High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32, 219-228. https://doi.org/10.1200/JCO.2013.51.8571

@article{1a9526dbbf964ff39c6a77cc36eb48e6,

title = "High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial",

abstract = "Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.",

keywords = "leukemia, leukemia",

author = "Roelof Willemze and Stefan Suciu and Giovanna Meloni and Boris Labar and Jean-Pierre Marie and Halkes, {Constantijn J. M.} and Petra Muus and Martin Mistrik and Sergio Amadori and Giorgina Specchia and Francesco Fabbiano and Francesco Nobile and Marco Sborgia and Andrea Camera and Selleslag, {Dominik L. D.} and {Lefre{\`r}E Sr.}, Francois and Domenico Magro and Simona Sica and Nicola Cantore and Meral Beksac and Zwi Berneman and Xavier Thomas and Lorella Melillo and Guimaraes, {Jose E.} and Pietro Leoni and Mario Luppi and Mitra, {Maria E.} and Dominique Bron and Georges Fillet and Marijt, {Erik W. A.} and Adriano Venditti and Anne Hagemeijer and Marco Mancini and Joop Jansen and Daniela Cilloni and Liv Meert and Paola Fazi and Marco Vignetti and Trisolini, {Silvia M.} and Franco Mandelli and {De Witte}, Theo",

year = "2014",

doi = "10.1200/JCO.2013.51.8571",

language = "English",

volume = "32",

pages = "219--228",

journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",

}

Willemze, R, Suciu, S, Meloni, G, Labar, B, Marie, J-P, Halkes, CJM, Muus, P, Mistrik, M, Amadori, S, Specchia, G, Fabbiano, F, Nobile, F, Sborgia, M, Camera, A, Selleslag, DLD, Lefrer̀E Sr., F, Magro, D, Sica, S, Cantore, N, Beksac, M, Berneman, Z, Thomas, X, Melillo, L, Guimaraes, JE, Leoni, P, Luppi, M, Mitra, ME, Bron, D, Fillet, G, Marijt, EWA, Venditti, A, Hagemeijer, A, Mancini, M, Jansen, J, Cilloni, D, Meert, L, Fazi, P, Vignetti, M, Trisolini, SM, Mandelli, F & De Witte, T 2014, 'High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 32, pagg. 219-228. https://doi.org/10.1200/JCO.2013.51.8571

High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. / Willemze, Roelof; Suciu, Stefan; Meloni, Giovanna et al.
In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 32, 2014, pag. 219-228.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

AU - Willemze, Roelof

AU - Suciu, Stefan

AU - Meloni, Giovanna

AU - Labar, Boris

AU - Marie, Jean-Pierre

AU - Halkes, Constantijn J. M.

AU - Muus, Petra

AU - Mistrik, Martin

AU - Amadori, Sergio

AU - Specchia, Giorgina

AU - Fabbiano, Francesco

AU - Nobile, Francesco

AU - Sborgia, Marco

AU - Camera, Andrea

AU - Selleslag, Dominik L. D.

AU - Lefrer̀E Sr., Francois

AU - Magro, Domenico

AU - Sica, Simona

AU - Cantore, Nicola

AU - Beksac, Meral

AU - Berneman, Zwi

AU - Thomas, Xavier

AU - Melillo, Lorella

AU - Guimaraes, Jose E.

AU - Leoni, Pietro

AU - Luppi, Mario

AU - Mitra, Maria E.

AU - Bron, Dominique

AU - Fillet, Georges

AU - Marijt, Erik W. A.

AU - Venditti, Adriano

AU - Hagemeijer, Anne

AU - Mancini, Marco

AU - Jansen, Joop

AU - Cilloni, Daniela

AU - Meert, Liv

AU - Fazi, Paola

AU - Vignetti, Marco

AU - Trisolini, Silvia M.

AU - Mandelli, Franco

AU - De Witte, Theo

PY - 2014

Y1 - 2014

N2 - Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.

AB - Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.

KW - leukemia

UR - http://hdl.handle.net/10807/50965

U2 - 10.1200/JCO.2013.51.8571

DO - 10.1200/JCO.2013.51.8571

M3 - Article

VL - 32

SP - 219

EP - 228

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

ER -

Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJM et al. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32:219-228. doi: 10.1200/JCO.2013.51.8571

High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo